• Xiaoyu Li, Xianzhi Zhao, Wen Song, Zibin Tian, Lin Yang, Qinghui Niu, Qi Zhang, Man Xie, Bin Zhou, Yonghong Xu, Jun Wu, and Cuiping Zhang.
• Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
• Yonsei Med. J. 2018 Jan 1; 59 (1): 202720-27.

PurposeThis study was aimed to investigate the effect of pseudolaric acid B (PAB) on proliferation, invasion and epithelial-to-mesenchymal transition (EMT) in pancreatic cancer cells and to explore the possible mechanism.Materials And MethodsThe pancreatic cancer cell line SW1990 was cultured and treated with PAB dose- and time-dependent manners. Cell proliferation and invasion ability were measured by MTT assay and Matrigel/Transwell test, respectively. Semi-quantitative real-time polymerase chain reaction and Western blotting were conducted to detect the expression of EMT markers and the key molecules. Finally, nude mice subcutaneous transplantation tumor model was used to confirm the therapy efficacy of PAB.ResultsPAB could inhibit SW1990 cell proliferation and invasion in time- and dose-dependent manners. Vimentin, fibronectin, N-cadherin, Snail, Slug, YAP, TEAD1, and Survivin were down-regulated (p<0.01), while E-cadherin, caspase-9, MST1, and pYAP were up-regulated (p<0.05). Combined PAB and gemcitabine treatment markedly restricted the tumor growth compared with gencitabin or PAB alone groups.ConclusionPAB could inhibit the proliferation and invasion ability of pancreatic cancer cells through activating Hippo-YAP pathway and inhibiting the process of EMT.© Copyright: Yonsei University College of Medicine 2018

45 keywords...

hide…